Ann: December 2018 Quarterly Activities and Cashflow Report, page-2

I find it odd that after Dayacann has completed 2 cultivation crops yet Auscann has zero receipts.......is no money being made from these 1st 2 crops? 
The 3rd crop in non-binding agreement MoU with Khiron sure to be zero dollar value also.

Low cash burn of $1M for the Qtr.

Apart from (empty) hard shell capsule to be completed during the year, doesn't seem like much other progress is planned, other than unmentioned clinical trials.

Could be a slow news year, but at least they are cashed up.